Advances toward the elucidation of hypertonic saline effects on pseudomonas aeruginosa from cystic fibrosis patients

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Michon, Anne Laure ^a,b   Jumas Bilak, Estelle ^a,c   Chiron, Raphael ^b   Lamy, Brigitte ^a,b   Marchandin, Helene ^a,b  

^a UNIV MONTPELLIER   (France)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM CHLORIDE;

ADOLESCENT; ADULT; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ADHERENCE; BACTERIUM ISOLATE; BIOFILM; CHILD; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYSTIC FIBROSIS; HUMAN; IN VITRO STUDY; INFANT; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY;

ANTI-BACTERIAL AGENTS; BIOFILMS; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SALINE SOLUTION, HYPERTONIC;

EID: 84896530424     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090164     Document Type: Article

References (34)

1. Clunes MT, Boucher RC (2007) Cystic Fibrosis: the mechanisms of pathogenesis of an inherited lung disorder. Drug Discov Today Dis Mech 4: 63-72. (Pubitemid 351966331)
2. Sibley CD, Rabin H, Surette MG (2006) Cystic fibrosis: a polymicrobial infectious disease. Future Microbiol 1: 53-61.
3. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL (2002) Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 34: 91-100. (Pubitemid 34809519)
4. Boucher RC (2007) Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 261: 5-16. (Pubitemid 46046468)
5. Reeves EP, Molloy K, Pohl K, McElvaney NG (2012) Hypertonic saline in treatment of pulmonary disease in cystic fibrosis. Scientific World Journal 465230.
6. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, et al. (2006) A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354: 229-240. (Pubitemid 43113028)
7. Dmello D, Nayak RP, Matuschak GM (2011) Stratified assessment of the role of inhaled hypertonic saline in reducing cystic fibrosis pulmonary exacerbations: a retrospective analysis. BMJ Open 1:e000019.
8. Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, et al. (1996) Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 21: 77-83. (Pubitemid 26098513)
9. Ballmann M, Von der Hardt H (2002) Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. J Cyst Fibros 1: 35-37.
10. Wark P, McDonald V (2009) Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev CD001506.
11. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, et al. (2006) Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 354: 241-250. (Pubitemid 43113029)
12. Cystic Fibrosis Consensus Conference May 17-18, 1994. Microbiology and infectious disease in cystic fibrosis. Bethesda, MD, Cystic Fibrosis Foundation, 1994; Vol. 5, Section 1, pp. 1-26.
13. Patel JB, Tenover FC, Turnidge JD, Jorgensen JH (2011) Susceptibility test methods: dilution and disk diffusion methods. In: Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW, editors. Manual of Clinical Microbiology, 10th edn. Washington, DC: American Society for Microbiology press, pp 1122-1143.
14. Courvalin P, Leclercq R, Rice L (2009) Antibiogram, 3rd edn. Washington, DC: American Society for Microbiology press.
15. Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M (2000) A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods 40: 175-179. (Pubitemid 30107900)
16. Deligianni E, Pattison S, Berrar D, Ternan NG, Haylock RW, et al. (2010) Pseudomonas aeruginosa Cystic Fibrosis isolates of similar RAPD genotype exhibit diversity in biofilm forming ability in vitro. BMC Microbiol 10: 38.
17. Pompilio A, Crocetta V, Scocchi M, Pomponio S, Di Vincenzo V, et al. (2012) Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and antibiofilm activity of natural and designed a-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. BMC Microbiol 12: 145.
18. Bye PT, Elkins MR (2007) Other mucoactive agents for cystic fibrosis. Paediatr Respir Rev 8:30-39. (Pubitemid 46523788)
19. Havasi V, Hurst CO, Briles TC, Yang F, Bains DG, et al. (2008) Inhibitory effects of hypertonic saline on P. aeruginosa motility. J Cyst Fibros 7: 267-269.
20. O'Toole GA, Kolter R (1998) Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol Microbiol 30: 295-304. (Pubitemid 28480181)
21. Behrends V, Ryall B, Wang X, Bundy JG, Williams HD (2010) Metabolic profiling of Pseudomonas aeruginosa demonstrates that the anti-sigma factor MucA modulates osmotic stress tolerance. Mol Biosyst 6: 562-569.
22. Williams HD, Behrends V, Bundy JG, Ryall B, Zlosnik JE (2010) Hypertonic saline therapy in cystic fibrosis: do population shifts caused by the osmotic sensitivity of infecting bacteria explain the effectiveness of this treatment? Front Microbiol 1: 120.
23. Abdelraouf K, Kabbara S, Ledesma KR, Poole K, Tam VH (2011) Effect of multidrug resistance-conferring mutations on the fitness and virulence of Pseudomonas aeruginosa. J Antimicrob Chemother 66: 1311-1317.
24. Bergsson G, Reeves EP, McNally P, Chotirmall SH, Greene CM, et al. (2009) LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. J Immunol 183: 543-551.
25. O'Connell OJ, O'Farrell C, Harrison MJ, Eustace JA, Henry MT, et al. (2011) Nebulized hypertonic saline via positive expiratory pressure versus via jet nebulizer in patients with severe cystic fibrosis. Respir Care 56: 771-775.
26. Robinson M, Hemming AL, Regnis JA, Wong AG, Bailey DL, et al. (1997) Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 52: 900-903. (Pubitemid 27473934)
27. Tarran R, Grubb BR, Parsons D, Picher M, Hirsh AJ, et al. (2001) The CF salt controversy: in vivo observations and therapeutic approaches. Mol Cell 8: 149-158. (Pubitemid 32772913)
28. Van der Waal SV, Van der Sluis LWM, Özok AR, Exterkate RA, van Marle J, et al. (2011) The effects of hyperosmosis or high pH on a dual-species biofilm of Enterococcus faecalis and Pseudomonas aeruginosa: an in vitro study. Int Endod J 44: 1110-1117.
29. Oguzhan N, Pala C, Sipahioglu MH, Cilan H, Durmaz S, et al. (2012) Locking tunneled hemodialysis catheters with hypertonic saline (26% NaCl) and heparin to prevent catheter-related bloodstream infections and thrombosis: a randomized, prospective trial. Ren Fail 34: 181-188.
30. Parmar JH, Bhartiya S, Venkatesh KV (2011) Characterization of the adaptive response and growth upon hyperosmotic shock in Saccharomyces cerevisiae. Mol Biosyst 7: 1138-1148.
31. Seo K, Lee JE, Lim MY, Ko G (2012) Effect of temperature, pH, and NaCl on the inactivation kinetics of murine norovirus. J Food Prot 75: 533-540.
32. Peters BM, Jabra-Rizk MA, O'May GA, Costerton JW, Shirtliff ME (2012) Polymicrobial interactions: impact on pathogenesis and human disease. Clin Microbiol Rev 25: 193-213.
33. Williamson SJ, Paul JH (2006) Environmental factors that influence the transition from lysogenic to lytic existence in the phiHSIC/Listonella pelagia marine phage-host system. Microb Ecol 52: 217-225. (Pubitemid 44392976)
34. Shkilnyj P, Koudelka GB (2007) Effect of salt shock on stability of lambdaimm434 lysogens. J Bacteriol 189: 3115-3123. (Pubitemid 46697401)